ATLAS projects focus on cancer, cardiovascular disease, neurological disease, and the use of AI in medicine, with attention to equity throughout.
Routine blood tests capture systemic inflammation (NLR, CRP, IL-6) and nutritional reserve (PNI, BMI, albumin), yet published cutoffs vary and real world cohorts are rarely compared with randomized trial data. This evidence synthesis combined 17 cohort studies from PubMed, Scopus, and Embase (596 records screened) with 12 post hoc analyses of phase 2 and 3 trials, including OAK, POPLAR, IMpower150, and CheckMate 017 and 057. Log hazard ratios were pooled with random effects models and Hartung Knapp intervals.
Inflammatory indices are robust prognostic markers, but cohort
estimates overstate trial level effects and need calibration before
clinical use. In the OAK trial, NLR carried similar risk under
docetaxel, so it behaved as a prognostic marker, while obesity favored
atezolizumab over docetaxel, suggesting nutrition may be predictive.
Team: Tanvi Chakka, Twesha Singh, Sriram Siva, Shivam
Loyalka
Among U.S. adults aged 21 to 75 newly diagnosed with cutaneous squamous cell carcinoma (SCC), does growing reliance on AI-assisted diagnostics such as FotoFinder Moleanalyzer Pro and DermaSensor influence disparities in specialist access, treatment continuity, and post-treatment health and financial well-being? This scoping review searched PubMed, Scopus, and EBSCO, screening 1,193 records and 20 full texts to include 16 studies, with 47 data fields extracted per study.
Without correction, AI diagnostics are more likely to widen SCC
outcome gaps for low income patients than close them. Biased training
data and weak reimbursement policy keep accurate tools in already well
resourced settings, but equity centered delivery models such as
teledermatology show that access gaps can close when care is designed
for it. Presented as an oral talk at the Stanford Lean Healthcare
conference.
Team: Swaroop Kadiyam, Siddharth Mothukuri, Rithvika
Venkatraman, Saisreeda Vutkuri
This team ran one systematic review in two versions, using the same evidence base with a general extraction and a sex stratified extraction.
How often do adult cardiovascular prediction models include socioeconomic and psychosocial predictors, and how do gains from machine learning compare with gains from adding social, biomarker, or genetic predictors? The review covered 40 prediction studies across community cohorts such as ARIC, UK Biobank, and ASPREE and disease specific groups including heart failure, atrial fibrillation, HIV, and rheumatoid arthritis.
Measuring social context mattered more than model complexity. In ARIC, Framingham scoring overestimated 10 year coronary risk by 17.5% in high SES adults and underestimated it by 24% in low SES adults, and adding individual SES removed this bias. A block group income measure worked about as well as individual SES, while a zip code measure only reduced the bias. Presented at MAA MathFest 2026 in Boston.
Across cardiovascular prediction models in adults, how often are socioeconomic and psychosocial determinants included, and does including them improve calibration, discrimination, or risk classification for women compared with models built only on traditional clinical predictors? The search of PubMed, Scopus, and Embase identified 2,770 records and 197 full texts, with 28 studies included.
Traditional clinical variables remained the core predictors,
socioeconomic measures were rarely included, and depression, stress,
social isolation, and caregiving burden were largely absent. Biomarkers
modestly improved prediction, but they cannot replace measuring the
social context that shapes women’s cardiovascular risk. Presented at the
Harvard T.H. Chan Women’s Health Conference.
Team: Srikrithi
Appikatla, Dhilan Avula, Venkat Narra, Nandita Sriram
For patients 18 and older, is an autonomous AI diagnostic system for diabetic retinopathy in a clinical setting more efficient than the standard referral to an eye care specialist? Diabetic retinopathy is a leading cause of preventable blindness, yet fewer than 1 in 1,000 eligible patients receive AI screening in primary care. Studies were screened in Rayyan with blinded and unblinded conflict resolution.
AI screening offers a reliable safety net for ruling out disease in
primary care, and pupil dilation protocols cut ungradable images sharply
(from 44.9% to 8.3% in Mayo Clinic telemedicine). Positive predictive
value varied widely (6 to 73%) with disease prevalence, and high upfront
cost and fragmented electronic health records still limit use. Embedding
AI directly into existing records systems could bring screening to rural
areas with few ophthalmologists.
Team: Raga Battu, Rithvik
Inampudi, Abhinav Premkumar, Pranjal Sabuwala
Among adults with Parkinson’s disease receiving dopaminergic therapy, which patient level risk factors are linked with faster neurodegeneration, such as greater annual UPDRS worsening, earlier dyskinesia onset, or faster DAT-SPECT decline? Following PRISMA guidelines, the team screened studies published from 2008 to 2025 in Rayyan, drew on cohorts and registries including PPMI, PRECEPT, PROPARK, and CamPaIGN, and pooled estimates with DerSimonian Laird random effects models.
Overall, prognostic factors were linked with a 42% higher risk of
adverse progression (pooled HR 1.42). GBA mutation carriers had more
than double the risk (HR 2.15), and female sex was associated with more
motor complications (2.36). Levodopa induced dyskinesia and GBA
mutations are the most consistent targets for risk stratification and
clinical trial enrichment.
Team: Soham Gupta, Rhea Jha, Arjun
Paunikar, Samhithaa Sivakumar
Our second cohort is developing new questions in AI and public health, including rare disease diagnosis with large language models, surgical access, and wearable based cardiovascular prediction for healthcare workers.